A decade of experience with an inpatient pneumococcal vaccination program
- Pharmacists able to raise vax rate in high-risk patients. // PharmacoEconomics & Outcomes News;10/1/2011, Issue 638, p4
The article discusses a research study which revealed the success of U.S. pharmacists in identifying at-risk patients and offering additional immunization services, like the pneumococcal vaccine, published in the August 19, 2011 issue of the journal "Vaccine."
- Curbing a bacterial menace. Foster, Stephan L. // Pharmacy Today;Aug2010 Supplement, p5
In this article, the author offers his views on the role played by pharmacists in addressing the pneumococcal immunization gap and reducing the impact of this virulent bacterial threat in the U.S. He believes that pharmacists are in the best position to help increase pneumococcal vaccine uptake...
- Vaccination delivery by chain pharmacies in California: Results of a 2007 survey. Pilisuk, Tammy; Goad, Jeffery; Backer, Howard // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2010, Vol. 50 Issue 2, p134
Objective: To better understand the practice standards and scope of pharmacist-administered vaccination services at chain pharmacies in California. Design: Cross sectional. Setting: California in 2006-2007. Participants: Eight state-level immunization coordinator corporate liaisons to chain...
- Immunization of Humans with Recombinant Pneumococcal Surface Protein A (rPspA) Elicits Antibodies That Passively Protect Mice from Fatal Infection with Streptococcus pneumoniae Bearing Heterologous PspA. Briles, David E.; Hollingshead, Susan K.; King, Janice; Swift, Amy; Braun, Patricia A.; Park, Moon K.; Ferguson, Laura M.; Nahm, Moon H.; Nabors, Gary S. // Journal of Infectious Diseases;12/1/2000, Vol. 182 Issue 6
Pneumococcal surface protein A (PspA), a cross-reactive protein expressed by all pneumo-cocci, is known to elicit an antibody in animals that can passively protect mice from infection with Streptococcus pneumoniae. A phase I trial with recombinant PspA showed the protein to be immunogenic in...
- Introduction of pneumococcal vaccine to standard immunisation programmes in Europe: what are we waiting for? Heininger, Ulrich // European Journal of Pediatrics. Supplement;2002, Vol. 161, pS125
Focuses on the introduction of pneumococcal vaccine to standard immunization programs in Europe. Efficacy, efficiency and safety of pneumococcal conjugate vaccine.
- Method for Ascertaining Denominators for Evaluation of Population Coverage with Pneumococcal Vaccine. Schopflocher, Donald P.; Russell, Margaret L. // Canadian Journal of Public Health;Sep/Oct2003, Vol. 94 Issue 5, p377
Background: Immunization programs may collect numerator data for the estimation of pneumococcal vaccine coverage, but program evaluators do not have appropriate denominator data for estimation of pneumococcal vaccine coverage, particularly among those eligible for vaccine on the grounds of...
- PCV-10 vax cost effective vs PCV-13. // PharmacoEconomics & Outcomes News;6/25/2011, Issue 631, p7
The article discusses a cost-utility analysis conducted in an Argentine healthcare system in 2011 which shows that pneumococcal 10-valent vaccine conjugate (PCV-10) is better value for money for routine child immunisation than pneumococcal 13-valent-CRM197 vaccine conjugate (PCV-13).
- Cost a barrier for self-paid vaccination in Poland. // PharmacoEconomics & Outcomes News;11/2/2013, Issue 690, p5
The article discusses the results of a study which appeared in an article by M Ganczak et al. in the October 8, 2013 issue of "Vaccine," revealing that immunisation coverage for self-paid vaccines among children aged 0-5 years in Poland is largely shaped by the cost of the vaccine.
- Pneumococcal Vaccine Effectiveness. // Pediatrics for Parents;Jul/Aug2013, Vol. 29 Issue 7/8, p1
The article provides information on a report regarding immunization program in Nicaragua that added 13-valent pneumococcal vaccine to its national immunization schedule in 2010 which results to reduce illness and saved lives.